NCT01386385 2026-03-18
Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
Clinical Trials
53 trialsNCT06694454 2026-03-18
Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)
National Institutes of Health Clinical Center (CC)
Phase 1/2 Not yet recruiting
NCT04083599 2026-03-16
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
Genmab
Phase 1/2 Active not recruiting
NCT04165070 2026-03-16
MK-3475-01A
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT07472647 2026-03-16
SYS6090 Combination Therapy in Advanced Lung Cancer
Shanghai JMT-Bio Inc.
Phase 1/2 Not yet recruiting
NCT05904379 2026-03-09
AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer
Akeso
Phase 1/2 Active not recruiting
NCT06047379 2026-03-02
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
Phase 1/2 Recruiting
NCT06996782 2026-02-24
ALTAIR
AstraZeneca
Phase 1/2 Recruiting
NCT04644068 2026-02-19
PETRA
AstraZeneca
Phase 1/2 Active not recruiting
NCT04198766 2025-12-18
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Inhibrx Biosciences, Inc
Phase 1/2 Active not recruiting
NCT05664971 2025-12-02
JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer
Shanghai Junshi Bioscience Co., Ltd.
Phase 1/2 Completed
NCT02711137 2025-10-21
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Incyte Corporation
Phase 1/2 Terminated
NCT05652686 2025-09-23
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Phanes Therapeutics
Phase 1/2 Recruiting
NCT06016270 2025-09-05
A Study of hSTC810 in Combination With Paclitaxel in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer
STCube, Inc.
Phase 1/2 Terminated
NCT05543629 2025-03-18
A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer
Bristol-Myers Squibb
Phase 1/2 Terminated
NCT03693612 2024-08-28
GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors
GlaxoSmithKline
Phase 1/2 Completed
NCT04647344 2024-04-25
A Study of AK104 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Akeso
Phase 1/2 Completed
NCT02567799 2024-01-25
NSCLC
Humanetics Corporation
Phase 1/2 Completed
NCT03840915 2023-08-21
M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC)
EMD Serono
Phase 1/2 Completed
NCT02983045 2023-03-13
PIVOT-02
Nektar Therapeutics
Phase 1/2 Completed
NCT03138889 2023-03-10
PROPEL
Nektar Therapeutics
Phase 1/2 Terminated
NCT02039674 2022-11-08
MK-3475-021
Merck Sharp & Dohme LLC
Phase 1/2 Completed
NCT03085914 2022-09-23
A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
Incyte Corporation
Phase 1/2 Completed
NCT04210037 2022-07-12
Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer
Ascentage Pharma Group Inc.
Phase 1/2 Terminated
NCT00618917 2021-11-12
MnSOD
University of Pittsburgh
Phase 1/2 Terminated
NCT01757288 2021-10-28
Phase I/II NabPaclitaxel, Paclitaxel&Carboplatin w RTX Followed by Consolidation in Patients w Favorable Prognosis Inoperable Stage IIIA/B NSCLC
University of Texas Southwestern Medical Center
Phase 1/2 Completed
NCT02574078 2021-05-06
CheckMate370
Bristol-Myers Squibb
Phase 1/2 Completed
NCT01268059 2020-12-23
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Untreated, Advanced Non-Small Cell Lung Cancer
MedImmune LLC
Phase 1/2 Terminated
NCT00278148 2020-07-20
Erlotinib, Paclitaxel, and Carboplatin Combined With Radiation Therapy for Stage III Non-Small Cell Lung Cancer
Case Comprehensive Cancer Center
Phase 1/2 Completed
NCT01310244 2020-01-06
MTD Study PXD-101 in Combination With Paclitaxel + Carboplatin in Chemotherapy-Naive Patients With Stage IV NSCLC
Acrotech Biopharma Inc.
Phase 1/2 Completed
NCT02920450 2019-10-04
UF-STO-LUNG-002
University of Florida
Phase 1/2 Terminated
NCT00547443 2019-01-10
Sorafenib and High-Dose Carboplatin, Paclitaxel, and External-Beam Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer
University of Texas Southwestern Medical Center
Phase 1/2 Withdrawn
NCT01234038 2018-06-27
NSCLC
Ionis Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT01090830 2018-02-23
HCH003
Holy Cross Hospital, Florida
Phase 1/2 Terminated
NCT00023673 2017-12-22
Radiation Therapy Combined With Paclitaxel and Carboplatin in Treating Patients With Stage III Non-Small Cell Lung Cancer
Radiation Therapy Oncology Group
Phase 1/2 Completed
NCT00093756 2017-12-07
Bortezomib, Paclitaxel, Carboplatin and Radiation Therapy for Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00280150 2017-06-19
Combination Chemotherapy, Bev, RT, and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 1/2 Completed
NCT00662311 2017-06-14
Vorinostat, Paclitaxel, and Radiation Therapy in Treating Patients Unable to Tolerate Cisplatin With Stage III Non-Small Lung Cancer That Cannot Be Removed By Surgery
University of Washington
Phase 1/2 Terminated
NCT00728845 2017-05-23
Hydroxychloroquine, Carboplatin, Paclitaxel, and Bevacizumab in Recurrent Advanced Non-Small Cell Lung Cancer
Rutgers, The State University of New Jersey
Phase 1/2 Terminated
NCT02204345 2017-01-25
A Study Evaluating RO5479599 in Combination With Carboplatin and Paclitaxel in Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) of Squamous Histology
Hoffmann-La Roche
Phase 1/2 Terminated
NCT00006012 2016-07-06
Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer
Alliance for Clinical Trials in Oncology
Phase 1/2 Completed
NCT00094835 2016-03-24
Study to Evaluate Motesanib With or Without Carboplatin/Paclitaxel or Panitumumab in the Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Amgen
Phase 1/2 Completed
NCT01100931 2015-10-19
A Phase I/II Study of Paclitaxel, Carboplatin and YM155 (Survivin Suppressor) in Subjects With Solid Tumors (Phase I) and Advanced Non-Small Cell Lung Carcinoma (Phase II)
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT00614484 2014-05-22
Chemotherapy and Proton Radiation for the Treatment of Locally Advanced Lung Cancer
Loma Linda University
Phase 1/2 Terminated
NCT02044601 2014-04-24
Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT)
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT00004160 2013-11-26
Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Surgically Removed
University of Alabama at Birmingham
Phase 1/2 Completed
NCT00004159 2013-11-20
Gemcitabine Plus Paclitaxel in Treating Patients With Advanced Non-small Cell Lung Cancer or Other Solid Tumor
University of Alabama at Birmingham
Phase 1/2 Terminated
NCT00147537 2013-10-30
Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung Cancer
Pfizer
Phase 1/2 Completed
NCT00005032 2013-02-11
Bcl-2 Antisense Oligodeoxynucleotide G3139 and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer
University of Chicago
Phase 1/2 Completed
NCT00004093 2012-06-06
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
Northwestern University
Phase 1/2 Terminated